List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 4442 studies with search of: AIDS
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT);   Biological: rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT);   Biological: Empty TBC-FPV;   Biological: TBC-MVA and TBC-FPV
2 Completed A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group
Conditions: HIV Infections;   Measles
Interventions: Biological: Attenuvax;   Biological: M-M-R-II
3 Recruiting A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication
Conditions: HIV-1;   HIV Infections
Interventions: Other: VircoType HIV-1 genotypic interpretation;   Other: Local Expert Review of HIV Genotypic resistance testing
4 Recruiting Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-uninfected, Circumcised Men and Transgender Women Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: DNA plasmid vaccine;   Biological: HIV-1 recombinant adenovirus vaccine;   Biological: DNA plasmid vaccine placebo;   Biological: HIV-1 recombinant adenovirus vaccine placebo
5 Completed A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203);   Biological: Aluminum hydroxide;   Biological: MF59;   Biological: rgp120/HIV-1MN
6 Completed A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1;   Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1;   Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: rgp120/HIV-1 SF-2
7 Active, not recruiting A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2;   Biological: Placebo version of rgp120/HIV-1MN;   Biological: Placebo version of rgp120/HIV-1SF2
8 Suspended Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults
Condition: HIV Infections
Interventions: Biological: MRKAd5 HIV-1 gag/pol/nef;   Other: Placebo
9 Recruiting Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
Conditions: HIV-1 Infections;   HIV Infections
Interventions: Drug: Tenofovir Disoproxil Fumarate (TDF);   Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF);   Drug: Placebo
10 Completed Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVADV027-00-VP;   Biological: VRC-HIVADV038-00-VP;   Biological: VRC-HIVDNA044-00-VP
11 Completed Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-1 gag DNA;   Biological: IL-15 DNA adjuvant;   Biological: IL-12 DNA adjuvant
12 Completed A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1;   Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65)
13 Completed A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega
Condition: HIV Infections
Intervention: Biological: HIV-1 Immunogen
14 Active, not recruiting Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection
Condition: HIV Infections
Interventions: Biological: MRKAd5 HIV-1 gag/pol/nef;   Biological: MRKAd5 HIV-1 gag/pol/nef placebo
15 Completed Evaluation of the Preventing AIDS Through Live Movement and Sound (PALMS) Intervention for Minority Adolescents
Condition: HIV Infections
Intervention: Behavioral: Preventing AIDS Through Live Movement and Sound (PALMS)
16 Completed Improving HIV Screening With Nurse-Based Rapid Testing/Streamlined Counseling
Conditions: Health Care Quality, Access, and Evaluation;   Delivery of Health Care;   Immune System Diseases;   HIV Infections
Interventions: Other: Rates of HIV testing and receipt of results;   Other: Sexual risk reduction; HIV knowledge improvement
17 Completed Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients
Condition: HIV Infections
Intervention: Biological: EP HIV-1090
18 Completed A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults
Condition: HIV Infections
Interventions: Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1;   Biological: QS-21;   Biological: rgp120/HIV-1MN
19 Recruiting Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
Condition: Human Immunodeficiency Virus
Interventions: Drug: 3-drug anti-HIV therapy;   Drug: Raltegravir
20 Recruiting Preventing Sexual Transmission of HIV With Anti-HIV Drugs
Condition: HIV Infections
Interventions: Drug: Atazanavir;   Drug: Didanosine;   Drug: Efavirenz;   Drug: Emtricitabine/Tenofovir disoproxil fumarate;   Drug: Lamivudine;   Drug: Lopinavir/Ritonavir;   Drug: Nevirapine;   Drug: Stavudine;   Drug: Tenofovir disoproxil fumarate;   Drug: Zidovudine/Lamivudine

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services